While Congress also amended section ''824(a) to add to the current bases for denial, revocation, or suspension of registration a finding that registration would be inconsistent with the public interest on the grounds specified in [section] 823, which will include consideration of the new factors added by'' the amendment, *id.* at 266–67, Congress did not otherwise alter the text of section 824(a), which makes clear that the various paragraphs of this provision are findings, each of which provides an independent and adequate ground to support agency action against a registration, and not discretionary factors to be considered by the Agency. Indeed, Respondent points to nothing in the language of section 824 or the CSA's legislative history to support his position, which would fundamentally alter the scope of the Agency's authority under section 824.

I therefore reject Respondent's contentions. Based on the ALJ's finding that Respondent is not currently authorized to dispense controlled substances in Mississippi, the State in which he holds the DEA registration at issue in this proceeding, I will adopt the ALJ's recommended order that I revoke his registration.

Order

Pursuant to the authority vested in me by 21 U.S.C. 824(a), as well as 28 CFR 0.100(b), I order that DEA Certificate of Registration No. AF2451261 issued to Arnold E. Feldman, M.D., be, and it hereby is, revoked. This *Order* is effective immediately.[9]

Dated: November 13, 2017.

Robert W. Patterson,

Acting Administrator.

[FR Doc. 2017–25287 Filed 11–21–17; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Importer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration as importers of various classes of schedule I or II controlled substances.

SUPPLEMENTARY INFORMATION: The companies listed below applied to be registered as importers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for these notices.

Company	FR Docket	Published
Almac Clinical Services Incorp (ACSI)	82 FR 37114	August 8, 2017.
Stepan Company	82 FR 41054	August 29, 2017.
Fresenius Kabi USA, LLC	82 FR 41053	August 29, 2017.
Cambrex Charles City	82 FR 41055	August 29, 2017.
Spex Certiprep Group, LLC	82 FR 42120	September 6, 2017.
Akorn, Inc	82 FR 42117	September 6, 2017.
Fisher Clinical Services, Inc	82 FR 42121	September 6, 2017.
Siegfried USA, LLC	82 FR 42117	September 6, 2017.
Mylan Pharmaceuticals, Inc	82 FR 42120	September 6, 2017.
KVK-Tech, Inc	82 FR 42119	September 6, 2017.
Cerilliant Corporation	82 FR 43404	September 15, 2017.
Unither Manufacturing LLC	82 FR 43571	September 18, 2017.
Mylan Pharmaceuticals, Inc	82 FR 43572	September 18, 2017.
Catalent Centers, LLC	82 FR 43569	September 18, 2017.
Specgx LLC	82 FR 43571	September 18, 2017.
Sharp Clinical Services, Inc	82 FR 43572	September 18, 2017.
Cody Laboratories, Inc	82 FR 45612	September 29, 2017.
Bellwyck Clinical Services	82 FR 45613	September 29, 2017.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrants to import the applicable basic classes of schedule I or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each company's maintenance of effective controls against diversion by inspecting and testing each company's physical security systems, verifying each company's compliance with state and local laws, and reviewing each company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I or II controlled substances to the above listed persons.

Dated: November 16, 2017.

Demetra Ashley,

Acting Assistant Administrator.

[FR Doc. 2017–25284 Filed 11–21–17; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Linda M. Shuck, D.O.; Decision and Order

On July 25, 2017, the Assistant Administrator, Diversion Control Division, Drug Enforcement Administration, issued an Order to Show Cause to Linda M. Shuck (Registrant), of Dobson, North Carolina. The Show Cause Order proposed the revocation of Registrant's Certificate of Registration, on the ground that she

[9] While the Mississippi Board Order was based on the Louisiana Board's Order, as noted in the former Acting Administrator's Decision and Order which revoked Respondent's Louisiana registration, the Louisiana Board found proved the sixth charge of the Administrative Complaint in that proceeding, in that Respondent violated state law by ''[p]rescribing, dispensing, or administering legally controlled substances or any dependency-inducing medication without legitimate medical justification thereof or in other than a legal or legitimate manner.'' *See* 82 FR at 39618 n.8 (2017); *see also* Mot. for Summ. Disp., Appendix B, at 22, 24 (Louisiana Board Order at 12, 14). For the same reasons as those cited by the former Acting Administrator, I find that the public interest necessitates that this Order be effective immediately. *See also* 21 CFR 1316.67.